Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA

Atika Capital Management LLC bought a new stake in shares of Zura Bio Limited (NASDAQ:ZURA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 276,000 shares of the company’s stock, valued at approximately $1,195,000. Atika Capital Management LLC owned approximately 0.42% of Zura Bio at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Forefront Wealth Partners LLC bought a new position in shares of Zura Bio during the 3rd quarter worth approximately $93,000. Savant Capital LLC increased its stake in shares of Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after acquiring an additional 21,249 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Zura Bio during the 1st quarter valued at $72,000. Finally, Jane Street Group LLC acquired a new position in shares of Zura Bio during the 2nd quarter valued at $113,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Insider Activity

In other Zura Bio news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of Zura Bio stock in a transaction dated Thursday, February 26th. The stock was purchased at an average cost of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the acquisition, the insider directly owned 6,552,725 shares of the company’s stock, valued at $40,954,531.25. This represents a 43.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 14.23% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on ZURA shares. Chardan Capital restated a “buy” rating and issued a $10.00 price target on shares of Zura Bio in a report on Friday, November 14th. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. Wedbush began coverage on Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zura Bio currently has an average rating of “Moderate Buy” and a consensus price target of $11.60.

Zura Bio Trading Up 1.3%

Shares of ZURA stock opened at $6.99 on Thursday. The firm has a fifty day simple moving average of $6.02 and a two-hundred day simple moving average of $4.35. Zura Bio Limited has a 12 month low of $0.97 and a 12 month high of $7.44. The firm has a market capitalization of $454.49 million, a PE ratio of -10.75 and a beta of 0.18.

Zura Bio Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.